Citations 1
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Murthy, Hemant S. , Zhang, Mei‐Jie , Chen, Karen , Ahmed, Sairah , Ganguly, Siddhartha , Kansagra, Ankit , Michelis, Fotios V. , Nishihori, Taiga , Patnaik, Mrinal M. , Aljurf, Mahmoud , Arai, Yasuyuki , Badar, Talha , Ballen, Karen K. , Bejanyan, Nelli , Brown, Valerie I. , Martino, Rodrigo , Cahn, Jean‐Yves , Castillo, Paul , Černý, Jan , Copelan, Edward A. , Daly, Andrew , Freytes, César O. , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Jamy, Omer , Joseph, Jacinth , Kanakry, Christopher G. , Khera, Nandita , Krem, Maxwell M. , Kuwatsuka, Yachiyo , Lekakis, Lazaros J. , Liu, Hongtao , Modi, Dipenkumar , Munshi, Pashna N. , Palmisiano, Neil , Rizzieri, David A. , Seo, Sachiko , Sharma, Akshay , Sohl, Melhm, Solomon, Scott R. , Ulrickson, Matthew L. , Üstün, Celalettin , Poel, Marjolein van der , Verdonck, Leo F. , Wagner, John L. , Wang, Trent , Wirk, Baldeep , Zeidan, Amer M. , Litzow, Mark R. , Weisdorf, Daniel J. , Saber, Wael , Kharfan‐Dabaja, Mohamed A. , Kansagra, Ankit , Michelis, Fotios V , Nishihori, Taiga , Patnaik, Mrinal , Arai, Yasuyuki , Badar, Talha , Bejanyan, Nelli , Bhatt, Vijaya Raj , Chhabra, Saurabh , Dholaria, Bhagirathbhai R , Diaz Perez, Miguel Angel , Freytes, Cesar O , Hashmi, Shahrukh K , Jamy, Omer , Krem, Maxwell M , Lazarus, Hillard M , Liu, Hongtao , Modi, Dipenkumar , Mussetti, Alberto , Patel, Sagar , Shah, Mithun V , Sharma, Akshay , Ustun, Celalettin , Wagner, John , Litzow, Mark R. , Hourigan, Christopher S , Weisdorf, Dan , Kharfan-Dabaja, Mohamed A , Murthy, Hemant S , Martino, Rodrigo , Ahmed, Sairah , Zeidan, Amer M , Deotare, Uday , Abid, Muhammad Bilal , Bacher, Ulrike , Badawy, Sherif M. , Battiwalla, Minoo , Beitinjaneh, Amer , Bhatt, Vijaya Raj , Chhabra, Saurabh , Dholaria, Bhagirathbhai , Díaz, Miguel Ángel , Grunwald, Michael R. , Lazarus, Hillard M. , Mussetti, Alberto , Patel, Sagar S. , Shah, Meera , Kebriaei, Partow , Hourigan, Christopher S.
Blood Advances | October 4, 2023 | Volume: 7 | Issue: 22 | Pages: 7007-7016
10.1182/bloodadvances.2023011308
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.